An excerpt from the press release. Full release.
“Doctors often rely on biomarkers – objective, easily measured biological features that indicate underlying pathology— to support accurate diagnosis and treatment efforts. Blood pressure, for example, is a widely-used biomarker for cardiovascular disease. Today, no comparable measures exist for FTD.
After reviewing proposals from 23 leading researchers worldwide, an expert panel has selected five researchers for multi-year FTD Biomarker awards:
- Randall Bateman, MD, Washington University, St. Louis.
- Christian Haas, PhD, Ludwig Maximilian University & the German Centre for Neurodegenerative Diseases, Munich.
- Leonard Petrucelli, PhD, Mayo Clinic, Jacksonville.
- Jonathan Rohrer, MRCP, PhD, University College London, UK.
- Judith Steen, PhD, Boston Children’s Hospital.
Biomarkers will help doctors to diagnose FTD, track its progression, and evaluate potential treatments. These efforts could also benefit research targeting diseases like Alzheimer’s, Parkinson’s and ALS.”
Visit the AFTD site for more details about the FTD Biomarkers Initiative.